← Leaderboards
Maria Eugenia Figueroa
University Of Michigan At Ann Arbor
$4,621,290
Attributed
$12,503,993
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2015–23$2.5M$1.9M$1.3M$625K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$12,503,993 · 4
By mechanism
RC2$6,432,141 · 1
R01$4,814,710 · 2
T32$1,257,142 · 1
Top collaborators
- John Hackett Bushweller8 shared
- Charles S Hemenway8 shared
- Nancy J Zeleznik-Le8 shared
- Mark D Fleming5 shared
- Robert Coleman Lindsley5 shared
- Akiko Shimamura5 shared
- James W Harbour2 shared
- Lluis Morey2 shared
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Theodora S Ross$5,900,708
- Andrew George Muntean$2,683,778
- Arul M Chinnaiyan$35,112,976
- Jolanta Grembecka$12,187,788
- Daniel S Wechsler$2,458,730
Others in their field
Top investigators on “Epigenetic Process”
- James E. Gern · University Of Wisconsin-Madison$115,652,679
- Richard A Gibbs · Baylor College Of Medicine$86,065,396
- Lisa P Jacobson · Johns Hopkins University$67,179,266
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$58,922,015
- Leonardo Trasande · New York University School Of Medicine$52,109,279
- Linda M Brzustowicz · Rutgers The St Univ Of Nj New Brunswick$47,855,284
Research focus
Epigenetic ProcessHematopoiesisGenesLeukemiaComplexBlood CellsBloodPhenotypeCellsGrantIn VivoStructureTranscriptome SequencingGene ExpressionEnhancersGenomeBaseGenetic TranscriptionDiagnosisC-TerminalBiochemicalDrug DevelopmentEpigenomicsChromatin
Grant awards (22)
Systems Biology of Bone Marrow Failure and MDS for Precision Medicine$1,271,028
RC2 · FY2023 · DK
AF9(MLLT3) Function in Leukemia and Normal Hematopoiesis$589,759
R01 · FY2023 · CA
AF9(MLLT3) Function in Leukemia and Normal Hematopoiesis$65,778
R01 · FY2023 · CA
Systems Biology of Bone Marrow Failure and MDS for Precision Medicine$1,271,028
RC2 · FY2022 · DK
AF9(MLLT3) Function in Leukemia and Normal Hematopoiesis$589,759
R01 · FY2022 · CA
Cancer Epigenetics Training Program$268,032
T32 · FY2022 · CA · contact PI
AF9(MLLT3) Function in Leukemia and Normal Hematopoiesis$65,778
R01 · FY2022 · CA
Systems Biology of Bone Marrow Failure and MDS for Precision Medicine$1,271,028
RC2 · FY2021 · DK
AF9(MLLT3) Function in Leukemia and Normal Hematopoiesis$601,794
R01 · FY2021 · CA
Cancer Epigenetics Training Program$274,719
T32 · FY2021 · CA · contact PI
AF9(MLLT3) Function in Leukemia and Normal Hematopoiesis$67,800
R01 · FY2021 · CA
Systems Biology of Bone Marrow Failure and MDS for Precision Medicine$1,278,845
RC2 · FY2020 · DK
AF9(MLLT3) Function in Leukemia and Normal Hematopoiesis$617,133
R01 · FY2020 · CA
Cancer Epigenetics Training Program$292,785
T32 · FY2020 · CA · contact PI
Systems Biology of Bone Marrow Failure and MDS for Precision Medicine$1,340,212
RC2 · FY2019 · DK
AF9(MLLT3) Function in Leukemia and Normal Hematopoiesis$642,234
R01 · FY2019 · CA
Cancer Epigenetics Training Program$282,924
T32 · FY2019 · CA · contact PI
Epigenetic biomarkers of response to Azacytidine in Myelodysplastic Syndromes$389,800
R01 · FY2018 · HL · contact PI
Cancer Epigenetics Training Program$138,682
T32 · FY2018 · CA
Epigenetic biomarkers of response to Azacytidine in Myelodysplastic Syndromes$390,375
R01 · FY2017 · HL · contact PI
Epigenetic biomarkers of response to Azacytidine in Myelodysplastic Syndromes$390,375
R01 · FY2016 · HL · contact PI
Epigenetic biomarkers of response to Azacytidine in Myelodysplastic Syndromes$404,125
R01 · FY2015 · HL · contact PI